Latest Conference Articles

The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.

Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.

Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.

Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.

Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.

RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

OTX-TKI remained generally well-tolerated in patients with moderately severe to severe NPDR across 48 weeks of the Phase 1 trial.

Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.

Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.

Phase 2a results demonstrated the efficacy and safety of orally administered CU06-1004 and may warrant further clinical studies in DME.

SGLT2 inhibitors may provide a favorable impact on the risk of sight-threatening diabetic retinal complications compared with other glucose-lowering therapies.

We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.

In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.

Carol Levy, MD, discusses INHALE-3 trial and how to incorporate individual patient-level factors into the management of patients with type 1 diabetes who could benefit from inhaled insulin.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, discuss recent data assessing ruxolitinib cream for patients as young as 2 years old with atopic dermatitis.

Davida Kruger, NP, joins the podcast to discuss updates in automated insulin delivery and continuous glucose monitoring systems from ADA 2024.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.